Exact Sciences stock is hot, ‘The Street’ says

Anticipating strong quarterly earnings for Exact Sciences, TheStreet believes the Cologuard-maker is in line for growth.

Advertisement

Here’s what you should know:

1. Exact reports its earnings Aug. 1.

2. The company’s stock has jumped 23 percent since the start of the year.

3. Six analysts have awarded Exact a “buy” rating.

4. Baird’s Catherine Schulte said, “We believe [Exact] is positioned to deliver on/exceed its 2018 guidance, with marketing campaigns, salesforce expansion and health system penetration all potentially helping [the second half] and beyond.” She also predicted Exact will hit around $1 billion in revenues in two years.

More articles on gastroenterology:
Key Surgical, ModMed & more — 3 GI company key notes
10 things to know about ASC coding audits
GI residents earn over $64K — Here’s which specialties rake in more

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.